Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01158950 · ClinicalTrials.gov registry record · NA
A Study of Neural Circuit Responses to Catechol-O-methyl Transferase (COMT) Inhibitors
A NA study, sponsored by University of California, San Francisco.
- Completed
- Registry status
- NA
- Development phase
- 26
- Enrollment target
NCT01158950 is a NA study that has completed, run by University of California, San Francisco. The registered enrollment target is 26 participants.
The verdict
NCT01158950, a NA study, has completed, sponsored by University of California, San Francisco.
- COMPLETED
- Registry status
- NA
- Development phase
- 26 participants
- Enrollment target
Study Summary
In this study, we seek to understand the effects of tolcapone, an FDA-approved COMT inhibitor, on reward choice and response inhibition, two measures we have previously shown to be altered in subjects with alcoholism. We now plan to test the hypothesis that COMT regulation of cortical dopamine levels is critical for regulation financial choices. Specifically, we propose that the lower levels of cortical dopamine present in individuals with the val158val COMT genotype reduces the inhibitory effect of frontal cortical areas on impulsive choice; an idea that extends previous hypotheses about the negative consequences of decreased prefrontal dopamine levels on inhibitory control. Moreover, this hypothesis suggests that inhibiting COMT may slow the degradation of dopamine and thereby decrease impulsivity.
Interventions
- OTHER Placebo
- DRUG Tolcapone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2010-03 |
| Est. Completion | 2018-12 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01158950
The ClinicalTrials.gov registry entry for NCT01158950 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 26 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, San Francisco, which has 1,713 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01158950 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01158950 about?
NCT01158950 is a clinical study titled "A Study of Neural Circuit Responses to Catechol-O-methyl Transferase (COMT) Inhibitors". In this study, we seek to understand the effects of tolcapone, an FDA-approved COMT inhibitor, on reward choice and response inhibition, two measures we have previously shown to be altered in subjects with alcoholism. We now plan to test the hypothesis that COMT regulation of cortical dopamine level...
What is the current status of trial NCT01158950?
This trial is currently completed. It is a NA study. The enrollment target is 26 participants. The study started on 2010-03. Estimated completion is 2018-12.
What interventions are being tested in trial NCT01158950?
The interventions under investigation include: Placebo (OTHER), Tolcapone (DRUG).
Who is sponsoring clinical trial NCT01158950?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.